Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar														
1. Name and Address of Reporting Person *- ADAMS JULIAN			2. Issuer Name and Ticker or Trading Symbol PIERIS PHARMACEUTICALS, INC. [PIRS]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 07/25/2016					-		re title below)		r (specify below)		
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)					-	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
BOSTON	N, MA 0210	09							-	Form filed by	More than One	Reporting Person		
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqu					s Acqui	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)				2A. Deemed Execution Date, any (Month/Day/Yea		Code (Instr.	(A	Securities Acquired A) or Disposed of (D) nstr. 3, 4 and 5)		5. Amount of Owned Follov Transaction(s) (Instr. 3 and 4	ving Report	ed (Ownership of orm:	Nature Indirect eneficial wnership
				(WOHAL) L	ray/ 1 car)	Cod	e V Ar	(A) or (D)	Price			(r Indirect (I) Instr. 4)	
								ed in this for splays a curr					ie	
								sed of, or Ben		Owned				
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transact	5. Nu 5. Nu Deriv Secu Acqu (A) c Disp	wative rities nired or osed of r. 3, 4,	options, con	vertible secur reisable and Date	7. Title Amour Underl Securit	e and nt of lying		9. Number o Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if	4. Transact	5. Nucion of Derivo Secu Acqu (A) co Dispo (D) (Insti	arrants, number varive rities nired or osed of r. 3, 4, 5)	options, cor 6. Date Exe Expiration (Month/Day	vertible secur reisable and Date y/Year)	7. Title Amour Underl Securit	e and nt of lying ties	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(Ownership Form of Derivative Security: Direct (D) or Indirect s) (I)	of Indire Beneficia Ownersh (Instr. 4)

Reporting Owners

Reporting Owner Name / Address	Relationships				
Reporting Owner France, Francess	Director	10% Owner	Officer	Other	
ADAMS JULIAN C/O PIERIS PHARMACEUTICALS, INC. 255 STATE STREET 9TH FLOOR BOSTON, MA 02109	X				

Signatures

/s/ Marc D. Mantell, Attorney-in-fact	07/26/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option will vest in four equal quarterly installments beginning from the date of grant and ending in twelve months, subject to the Reporting Person's continued service as a director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.